Teladoc (NYSE:TDOC) shares surged more than 5% after-hours following the company’s reported Q1 results, with EPS of ($0.42) coming in better than the consensus estimate of ($0.50).
Revenue increased 11% year-over-year to $629.24 million, beating the consensus estimate of $618.23M. Access fees revenue increased 12% year-over-year to $550.9M and other revenue increased 6% to $78.4M. U.S. revenues were up 10% to $541.7M, and International revenues increased 18% to $87.6M.
“Teladoc Health delivered strong first quarter results across all key financial and operating metrics to start the year. With a strong financial position, we are able to fund and invest in innovations and a world-class team of medical professionals as we support leading employers, health plans, hospital systems, and governments around the world,” said CEO Jason Gorevic.
For Q2, the company expects revenues in the range of $635M-$660M and EPS in the range of ($0.55)-($0.45).
For the full year, the company expects revenue in the range of $2.575 billion-$2.675 billion, and EPS in the range of ($1.70)-($1.25).